


Application No.: 10/749,121
 Applicants: Jeffrey O. Saunders et al.

CLAIM AMENDMENTS

Please replace all prior versions and listing of claims with the amended claims as follows:

1-4. (canceled)

5. (currently amended) The compound according to claim 1 wherein said A compound is selected from:





wherein


No.	-X-	-T _m Q
I-3	-CH ₂ -	
I-5	-CH ₂ -	
I-8	-CH ₂ -	
I-9	-CH ₂ -	
I-10	-CH ₂ -	

Application No.: 10/749,121
 Applicants: Jeffrey O. Saunders et al.

No.	X	T _m Q
I-11	-CH ₂ -	
I-12	-CH ₂ -	
I-13	-CH ₂ -	



Application No.: 10/749,121
Applicants: Jeffrey O. Saunders et al.




I-9

I-10

I-11

I-12



I-13

or

I-14

6-9. (canceled)

10. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1, and 3-5~~ and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

11. (original) The composition according to claim 10 wherein the composition comprises an additional therapeutic agent.

12-67. (canceled)

Application No.: 10/749,121
Applicants: Jeffrey O. Saunders et al.

68. (withdrawn) A method of treating or preventing a disease selected from autoimmune diseases, proliferative diseases, angiogenic disorders, and cancers in a patient comprising the step of administering to said patient a composition according to claim 10.

69. (withdrawn) The method according to claim 68 wherein said method is used to treat or prevent an autoimmune disease selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease.

70. (withdrawn) The method according to claim 68 wherein said method is used to treat or prevent a proliferative disease selected from acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HTLV-1-mediated tumorigenesis.

71. (withdrawn) The method according to claim 68 wherein said method is used to treat or prevent an angiogenic disorder selected from solid tumors, ocular neovascularization, and infantile haemangiomas.

72. (withdrawn) The method according to claim 68 wherein said method is used to treat or prevent a cancer selected from colon, breast, stomach, and ovarian cancer.

73. (withdrawn) The method according to claim 68 further comprising the step of administering to said patient an additional therapeutic agent.

74. (withdrawn) The method according to claim 73 wherein said additional therapeutic agent is selected from chemotherapeutic agents, anti-proliferative agents, and anti-inflammatory agents.